P1451: PRELIMINARY RESULTS FROM THE FLU/CY/ALEMTUZUMAB ARM OF THE PHASE I BALLI-01 TRIAL OF UCART22, AN ANTI-CD22 ALLOGENEIC CAR-T CELL PRODUCT, IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) CD22+ B-CELL ALL. (23rd June 2022) - Jain, N.; Roboz, G.; Konopleva, M.; Liu, H.; Schiller, G.; Jabbour, E.; Desai, P.; Whitfield, D.; Haider, A.; Zernovak, O.; Frattini, M.; Brownstein, C.; et al.